Arbutus is currently evaluating AB-506 for the treatment of chronic HBV infection. By inhibiting assembly of the viral capsid, AB-506 effectively blocks viral replication.
AB-506 showed attractive potency and PK in preclinical studies and has advanced into clinical development in a Phase 1a/1b study, initially in healthy volunteers followed by HBV patients. Top-line data from this ongoing study are anticipated in July 2019. Arbutus subsequently plans to evaluate a combination regimen, combining AB-506 with RNAi agent AB-729 and approved nucleoside analogs, with the goal of increasing cure rates in HBV patients.